GlassScriptPhysician profile
Mariadela Matute
NPI 1124318191
$6,443.06
in general payments reported to CMS, 2019-2025
24 companies · $797 in 2025
The $797 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,859 · 2022: $785 · 2023: $732 · 2024: $1,270 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Consulting Fee: $515 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.91 |
| Consulting Fee | $515.00 |
| Education | $164.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,502.84 | 2021-2025 | Niktimvo, Jakafi, Monjuvi |
| Pfizer INC. | $815.11 | 2021-2025 | |
| Janssen Biotech, INC. | $668.82 | 2022-2025 | Carvykti, Rybrevant, Tecvayli |
| Astellas Pharma US INC | $317.07 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $258.95 | 2021-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $253.83 | 2021 | |
| Genmab U.S., INC. | $246.87 | 2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $222.56 | 2022-2025 | Clonoseq |
| Stemline Therapeutics INC. | $124.74 | 2024 | Elzonris |
| Astrazeneca Pharmaceuticals LP | $124.33 | 2023-2024 | Lynparza |
| Celgene Corporation | $121.52 | 2021 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Talvey |
| E.R. Squibb & Sons, L.L.C. | $106.97 | 2022 | |
| Amgen INC. | $99.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $79.04 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $57.92 | 2024-2025 | Prevymis, Zerbaxa, Recarbrio |
| Abbvie INC. | $50.69 | 2023 | |
| Genentech USA, INC. | $39.71 | 2023-2024 | Columvi, Lunsumio |
| Sanofi-Aventis U.S. LLC | $34.34 | 2025 | |
| Daiichi Sankyo INC. | $29.92 | 2025 | Datroway |
| Sobi, INC | $28.62 | 2024 | |
| Glaxosmithkline, LLC. | $22.86 | 2024 | |
| Morphosys, US INC. | $22.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariadela Matute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.